Teriparatide
Also known as: Forteo, Bonsity, PTH (1-34)
Teriparatide (also called Forteo or Bonsity) is a research peptide in the PTH1 receptor agonist class. Teriparatide is recombinant human parathyroid hormone(1-34), the N-terminal fragment that carries the receptor-binding activity of the full hormone. It acts at the PTH1 receptor on osteoblasts.
For research use only.
Key Facts
- CAS
- 52232-67-4
- Molecular Weight (MW)
- 4117.8 g/mol
- Half-life
- About 1 hour after subcutaneous injection (Forteo label)
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- PTH1 receptor
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 2
- Listed offers
- 4
- Price per mg
- $128.00/mg
Research summary
FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk. 20 mcg SC daily; cumulative use generally ≤2 years.
Research evidence
- Regulatory review (FDA label)3 reviewed sources
- Controlled human trials1 reviewed source
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Teriparatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Teriparatide dosage evidence
Teriparatide has an FDA-approved human dosage of 20 mcg once daily by subcutaneous injection into the thigh or abdomen, for osteoporosis at high risk for fracture in postmenopausal women and men, including osteoporosis caused by long-term glucocorticoids. The Forteo label says use for more than 2 years in a lifetime should only be considered if fracture risk stays high or becomes high again. Teriparatide labels from other companies give the same dose.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 20 mcg once daily |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | Up to 2 years in a lifetime as a rule; longer only if fracture risk remains or returns to high |
| Half-life | About 1 hour after subcutaneous injection (Forteo label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Forteo, osteoporosisFDA-approved label · FDA prescribing information | Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk | 20 mcg | Subcutaneous, thigh or abdomen; not intravenous or intramuscular | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | In the label's postmenopausal study (1637 women), new vertebral fractures occurred in 5.0% with 20 mcg daily against 14.3% with placebo | FORTEO (teriparatide injection) — FDA prescribing information, DailyMed |
| FDA label — Teriparatide Injection (Teva), osteoporosisFDA-approved label · FDA prescribing information | The same three osteoporosis populations as Forteo | 20 mcg | Subcutaneous, thigh or abdomen | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | Treatment of osteoporosis | Teriparatide Injection (Teva) — FDA prescribing information, DailyMed |
| FDA label — Bonsity (Alvogen), osteoporosisFDA-approved label · FDA prescribing information | The same osteoporosis populations as Forteo | 20 mcg | Subcutaneous, thigh or abdomen | Once daily | — | Treatment of osteoporosis | BONSITY (teriparatide injection) — FDA prescribing information, DailyMed |
| Distal radius fracture healing — randomised trial (Aspenberg et al., 2010)Clinical trial · Randomised double-blind placebo-controlled trial | Postmenopausal women aged 45 to 85 with a distal radial fracture treated by closed reduction without surgery (n=102) | 20 mcg or 40 mcg, against placebo | Injection; route not stated in the indexed abstract | Once daily, started within 10 days of the fracture | 8 weeks | The primary hypothesis, that 40 mcg would shorten the time to cortical bridging, was not supported; in post hoc analysis healing was faster with 20 mcg than placebo (median 7.4 vs 9.1 weeks), which the authors say should be interpreted with caution | Aspenberg P et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010. |
Where sources disagree
- The current Forteo label lists osteosarcoma under Warnings and Precautions: it was seen in rats given teriparatide and has been reported in patients after marketing, although observational studies in humans have not shown an increased risk, and data beyond 2 years of use are limited. The label says to avoid teriparatide in people at higher baseline risk, including those with open growth plates, Paget's disease or other metabolic bone disease, bone metastases or skeletal cancer, prior radiation to the skeleton, or inherited conditions that predispose to osteosarcoma.
- The label also warns about hypercalcaemia, orthostatic hypotension (the first doses are given where the person can sit or lie down) and severe allergic reactions. It is not approved for children, and calcium and vitamin D are added when dietary intake is inadequate.
- The licensed products are prefilled pens of 560 mcg in 2.24 mL (250 mcg/mL) that deliver 28 daily doses of 20 mcg. Research-labelled teriparatide powder vials are not these products: their identity, content and sterility are not covered by any label cited here.
- Fracture healing is not an approved use. In the one randomised trial cited here, the higher 40 mcg dose did not significantly shorten healing against placebo; only a post hoc comparison favoured 20 mcg. The PTH(1-34) Analog profile describes generic and compounded preparations of the same molecule.
Reconstitution
Common research vial sizes: 1 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 1 mg | 1 mL | 1 mg/mL | 10 mcg per 0.01 mL |
| 1 mg | 2 mL | 0.5 mg/mL | 5 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Prefilled pen - no reconstitution needed
- Injection Sites
- ThighAbdomen
- Concentration Example
- Pre-filled pen: 20 mcg per dose (delivers 20 mcg in 80 mcL)
- Timing Notes
- Inject subcutaneously in thigh or abdomen, preferably at same time each day
- Expected Onset
- Bone density improvements typically seen within 6-12 months
Sequence & molecular data
| Molecular formula | C181H291N55O51S2 |
|---|---|
| Molecular weight | 4117.8 g/mol |
| CAS number | 52232-67-4 |
| Half-life | ~1 hour (sc) |
| Appearance | Sterile solution in prefilled pen |
| Formulation | Prefilled Pen |
| PubChem CID | 16133850 |
| FDA UNII | 10T9CSU89I |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Teriparatide is recombinant human parathyroid hormone(1-34), the N-terminal fragment that carries the receptor-binding activity of the full hormone. It acts at the PTH1 receptor on osteoblasts. The critical variable is exposure pattern rather than dose: continuous elevation of parathyroid hormone, as in hyperparathyroidism, favours RANKL-driven osteoclastic resorption and net bone loss, whereas brief daily peaks increase osteoblast number and survival and produce net bone formation. Intermittent once-daily dosing exploits that anabolic window. It is one of the few osteoporosis treatments that builds new bone rather than inhibiting its removal, and the effect declines after treatment stops unless followed by an antiresorptive.
Origin
Recombinant PTH(1–34).
Targets
Studies
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis
- Teriparatide (forteo) for osteoporsis
- Off-Label Use of Teriparatide in Spine
Research statistics
3,801 PubMed publications · 35.7% human clinical research · 162 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Teriparatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
Teriparatide side effects
The effects below are drawn from Teriparatide's prescribing information, which lists the full adverse-reaction data.
Side Effects
- Hypercalcemia
- Nausea
- Leg cramps
- Orthostasis
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Teriparatide: frequently asked questions
What is Teriparatide?
FDA-approved PTH(1–34) anabolic agent (Forteo/Bonsity) for osteoporosis at high fracture risk. 20 mcg SC daily; cumulative use generally ≤2 years.
How does Teriparatide work?
Teriparatide is recombinant human parathyroid hormone(1-34), the N-terminal fragment that carries the receptor-binding activity of the full hormone. It acts at the PTH1 receptor on osteoblasts.
Is Teriparatide FDA approved?
Yes. Teriparatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Teriparatide?
Reported half-life for Teriparatide is ~1 hour (sc). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Teriparatide banned in sport?
Teriparatide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Teriparatide?
Compounds most often compared with Teriparatide include Abaloparatide, PTH(1-34) Analog (Generic Teriparatide) and Bivalirudin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- FDA label — ForteoExternal reference
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials — Arch Osteoporos, 2024External reference
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial — Lancet, 2015External reference
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis — Osteoporos Int, 2025External reference
- Teriparatide (forteo) for osteoporsis — Med Lett Drugs Ther, 2003External reference
- Off-Label Use of Teriparatide in Spine — Cureus, 2021External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Teriparatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Teriparatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →